What is it about?
Inflammation is part of the development of heart disease and Pentraxin 3 is a new blood test for measuring this. We have shown that cxcl16 may be better than existing test for predicting badness (death, new heart attack or stroke) after a heart attack.
Photo by Kelly Sikkema on Unsplash
Why is it important?
This study is important because it supports that inflammation blood tests may have a place for doctors to assess the risk of badness for patients after a a heart attack. The new blood test seems to be better than the most studied one (C-reactive protein or CRP). This may allow doctors to choose treatment for individual patients and reduce risk of future badness, as well as stop treatment early for those of low risk.
Read the Original
This page is a summary of: Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial, European Heart Journal Acute Cardiovascular Care, April 2019, SAGE Publications, DOI: 10.1177/2048872619846334.
You can read the full text:
The following have contributed to this page